Sumatriptan News and Research

RSS

New AAN guidelines includes recommendations for treatment of migraine in children, teens

For children and teens with migraine, the pain and symptoms that accompany migraine attacks can be debilitating, resulting in missed school days, absence from social or sporting events, and affected home activities.

14 Aug 2019

New drug for migraine in the pipeline

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

18 Apr 2018

GammaCore both effective and cost effective for the treatment of cluster headache

A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account.

16 May 2016

FDA approves Lannett's ANDA for Sumatriptan Nasal Spray USP

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray, the therapeutic equivalent to the reference listed drug Imitrex Nasal Spray, of GlaxoSmithKline.

22 Feb 2016

FDA approves ZEMBRACESymTouch (sumatriptan succinate) injection for treatment of acute migraines

Dr. Reddy's Laboratories, announced today that the U.S. Food and Drug Administration has approved ZEMBRACESymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.

3 Feb 2016

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T.

3 Aug 2015

Presentation at International Headache Congress shows electroCore’s chronic cluster headache treatment to be cost-effective

Cluster headache is one of the worst pain conditions known to medical science and has few preventative treatment options, many of which have severe side effects...

19 May 2015

Montefiore and Einstein researchers to present new findings on neurological disorders at AAN 2015

Researchers from Montefiore Health System and Albert Einstein College of Medicine will present new findings on how to effectively treat migraine, and forecast the onset of pain in a number of neurological conditions including dementia in older adults.

21 Apr 2015

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015

FDA issues Complete Response letter for Avanir’s AVP-825 NDA

Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for AVP-825.

27 Nov 2014

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals, Inc. today announced the publication of results from TARGET, a pivotal phase III study evaluating the efﬁcacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available).

30 Oct 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

FDA accepts AVP-825 NDA for acute treatment of migraine

The U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered investigational drug-device combination product for the acute treatment of migraine.

27 Mar 2014

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Migraine affects an estimated 30 million people in the U.S, with the one year prevalence of migraine estimated at 12% of the general population, including 18% of all women and 6% of all men.

12 Apr 2013

Migraine severity may be predicted by blood levels of fat cell hormone

In a small, preliminary study of regular migraine sufferers, scientists have found that measuring a fat-derived protein called adiponectin (ADP) before and after migraine treatment can accurately reveal which headache victims felt pain relief.

18 Mar 2013

Strong placebo response key to adolescent migraine trial failures

A strong response to placebo is the main reason drug trials in the treatment of adolescent migraine have so far failed, say researchers.

31 Jan 2013

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011

U.S. District Court rules in favor of POZEN in Treximet patent litigation

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.

8 Aug 2011

Par Pharmaceutical reports second quarter total revenues of $224.2 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2011.

3 Aug 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011